Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) (PreCyssion)
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection With Gestational Age ≤ 14 Weeks - an Open-label, Single-arm, Prospective Trial Investigating Efficacy and Safety of Cytotect CP Biotest
Sponsor: Biotest
Terminated
Sponsor decision
This PHASE3 trial investigates Congenital Cytomegalovirus Infection and is currently terminated or withdrawn. Biotest leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Jun 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE3
-
Jan 2022 — Sep 2022 [monthly]
Recruiting PHASE3
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biotest
For direct contact, visit the study record on ClinicalTrials.gov .